ANI Pharmaceuticals, Inc.

NasdaqGM:ANIP Voorraadrapport

Marktkapitalisatie: US$1.1b

ANI Pharmaceuticals Beheer

Beheer criteriumcontroles 2/4

De CEO ANI Pharmaceuticals is Nikhil Lalwani, benoemd in Sep2020, heeft een ambtstermijn van 4.17 jaar. De totale jaarlijkse vergoeding van { bedraagt $ 8.08M, bestaande uit 9.5% salaris en 90.5% bonussen, inclusief aandelen en opties van het bedrijf. bezit rechtstreeks 1.91% van de aandelen van het bedrijf, ter waarde $ 21.28M. De gemiddelde ambtstermijn van het managementteam en de raad van bestuur bedraagt respectievelijk 3 jaar en 4.2 jaar.

Belangrijke informatie

Nikhil Lalwani

Algemeen directeur

US$8.1m

Totale compensatie

Percentage CEO-salaris9.5%
Dienstverband CEO4.2yrs
Eigendom CEO1.9%
Management gemiddelde ambtstermijn3yrs
Gemiddelde ambtstermijn bestuur4.2yrs

Recente managementupdates

Recent updates

Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

Nov 09
Here's Why ANI Pharmaceuticals (NASDAQ:ANIP) Can Manage Its Debt Responsibly

ANI Pharmaceuticals Is Acting Like It Is Being Acquired

Nov 02

ANI Pharmaceuticals: A Rare GARP Stock In An Overbought Market

Oct 11

There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

Sep 10
There's No Escaping ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Muted Revenues

ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Aug 14
ANI Pharmaceuticals' (NASDAQ:ANIP) Earnings Are Weaker Than They Seem

Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

Aug 08
Is ANI Pharmaceuticals (NASDAQ:ANIP) Using Too Much Debt?

ANI Pharmaceuticals: Tezruly Just Approved, 2 More NDAs Under Review And Alimera Science Acquisition Could Triple Revenue By 2028

Aug 02

Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

Jun 10
Subdued Growth No Barrier To ANI Pharmaceuticals, Inc.'s (NASDAQ:ANIP) Price

ANI Pharmaceuticals Is Undervalued, As Royalty Potential Is Overlooked

Jun 10

These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Feb 17
These 4 Measures Indicate That ANI Pharmaceuticals (NASDAQ:ANIP) Is Using Debt Reasonably Well

Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Nov 15
Additional Considerations Required While Assessing ANI Pharmaceuticals' (NASDAQ:ANIP) Strong Earnings

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Sep 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

Feb 22
Does ANI Pharmaceuticals (NASDAQ:ANIP) Have A Healthy Balance Sheet?

We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

Oct 28
We Think ANI Pharmaceuticals (NASDAQ:ANIP) Has A Fair Chunk Of Debt

ANI Pharma launches generic Prochlorperazine maleate tablets

Aug 29

ANI Pharmaceuticals' generic dexamethasone tablets get FDA approval

Aug 16

Analyse CEO-vergoeding

Hoe is Nikhil Lalwani's beloning veranderd ten opzichte van ANI Pharmaceuticals's winst?
DatumTotale vergoedingSalarisBedrijfswinsten
Sep 30 2024n/an/a

-US$9m

Jun 30 2024n/an/a

US$24m

Mar 31 2024n/an/a

US$31m

Dec 31 2023US$8mUS$764k

US$15m

Sep 30 2023n/an/a

US$10m

Jun 30 2023n/an/a

-US$8m

Mar 31 2023n/an/a

-US$28m

Dec 31 2022US$5mUS$737k

-US$50m

Sep 30 2022n/an/a

-US$69m

Jun 30 2022n/an/a

-US$65m

Mar 31 2022n/an/a

-US$63m

Dec 31 2021US$7mUS$715k

-US$43m

Sep 30 2021n/an/a

-US$22m

Jun 30 2021n/an/a

-US$17m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$4mUS$199k

-US$23m

Compensatie versus markt: De totale vergoeding ($USD 8.08M ) Nikhil } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de US markt ($USD 3.17M ).

Compensatie versus inkomsten: De vergoeding van Nikhil is gestegen terwijl het bedrijf verliesgevend is.

CEO

Nikhil Lalwani (46 yo)

4.2yrs

Tenure

US$8,078,353

Compensatie

Mr. Nikhil Lalwani served as a Director of Association for Accessible Medicines. He served as the Chief Executive Officer of InvaGen Pharmaceuticals, Inc. since October 24, 2016. Mr. Lalwani is a seasoned...

Leiderschapsteam

NaamPositieTenureCompensatieEigendom
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.3m
Stephen Carey
Senior VP of Finance & CFO8.5yrsUS$2.58m0.83%
$ 9.2m
Chad Gassert
Senior Vice President of Corporate Development & Strategy3yrsUS$1.90m1.24%
$ 13.8m
Christopher Mutz
Senior Vp & Head of Rare Disease3.8yrsUS$1.91m0.39%
$ 4.4m
Ori Gutwerg
Senior Vice President of Generics3.8yrsUS$1.94m0.40%
$ 4.4m
Muthusamy Shanmugam
Head of R&D3yrsgeen gegevens0.26%
$ 2.9m
James Marken
Senior Vice President of Operations8.5yrsUS$1.43m0.60%
$ 6.7m
Elizabeth Powell
Chief Compliance Officer & Head of Legal of Rare Disease2.8yrsgeen gegevensgeen gegevens
Meredith Cook
Senior VP2.3yrsgeen gegevens0.29%
$ 3.2m
Krista Davis
Senior VP & Chief Human Resources Officer2.2yrsgeen gegevens0.26%
$ 2.8m
Mary Pao
Chief Medical Officer2.8yrsgeen gegevensgeen gegevens
Thomas Rowland
Senior VP & Head of Established Brands3yrsgeen gegevens0.17%
$ 1.9m

3.0yrs

Gemiddelde duur

51.5yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van ANIP wordt beschouwd als ervaren (gemiddelde ambtstermijn 3 jaar).

Bestuursleden

NaamPositieTenureCompensatieEigendom
Nikhil Lalwani
President4.2yrsUS$8.08m1.91%
$ 21.3m
Muthusamy Shanmugam
Head of R&D3yrsgeen gegevens0.26%
$ 2.9m
Patrick Walsh
Independent Chairman6.5yrsUS$422.21k0.38%
$ 4.3m
Antonio Pera
Independent Director4.3yrsUS$393.25k0.16%
$ 1.8m
Thomas Haughey
Independent Director6.5yrsUS$412.21k0.26%
$ 2.9m
Jeanne Thoma
Independent Director4.3yrsUS$395.75k0.21%
$ 2.3m
Renee Tannenbaum
Independent Director2.7yrsUS$392.37k0.12%
$ 1.3m
Matthew Leonard
Independent Director1.3yrsUS$470.76k0.061%
$ 682.5k

4.2yrs

Gemiddelde duur

61.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van ANIP wordt beschouwd als ervaren (gemiddelde ambtstermijn 4.2 jaar).